Strengthening our domestic pharmaceutical supply chain so that we are less dependent on adversarial countries, like China, for essential medicines is a national security priority. We must promote American-made medicines.
Strengthen the domestic pharmaceutical supply chain and promote American-made medicines.
Occurrences
Evidence
Rep. Earl L. “Buddy” Carter introduced the Growing America’s Pharmaceutical Supply Act, saying it would alleviate drug shortages by giving outsourcing facilities more certainty to produce medications and increase domestic drug development.
Congress.gov shows H.R. 7528 was introduced by Rep. Carter and referred to the House Committee on Energy and Commerce; the bill remains at the introduced stage with no further action listed.
The White House proclaimed that pharmaceutical imports threaten national security and imposed tariffs/negotiation steps intended to shift production onshore and strengthen domestic pharmaceutical supply chains.
Assessments
Carter has materially pursued the promise in his current federal House service by introducing H.R. 7528, the Growing America's Pharmaceutical Supply Act, aimed at increasing domestic pharmaceutical production and easing shortages. However, the bill remains only introduced and referred to committee, so Carter has not delivered the promised policy outcome legislatively. The 2026 White House pharmaceutical import and tariff action advances the same domestic supply-chain goal during Carter's ongoing term, but it was an executive action by another official rather than a Carter-authored or Carter-controlled enactment. Taken together, the record supports meaningful effort and some policy movement, but not full fulfillment attributable to Carter.